(redirected from Fampyra)




Unknown. May increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.


Tablets (extended release): 10 mg

Indications and dosages

To improve walking in patients with multiple sclerosis

Adults: 10 mg P.O. q 12 hours

Dosage adjustments

• Mild renal impairment


• History of seizures

• Moderate or severe renal impairment


Use cautiously in:

• mild renal impairment

• pregnant or breastfeeding patients

• children younger than age 18 (safety and efficacy not established).


• Check creatinine clearance before starting drug.

• Administer with or without food.

Adverse reactions

CNS: insomnia, dizziness, headache, asthenia, balance disorder, paresthesia, seizures

EENT: nasopharyngitis, pharyngolaryngeal pain

GI: nausea, constipation, dyspepsia

GU: urinary tract infection

Musculoskeletal: back pain

Other: multiple sclerosis relapse



Patient monitoring

Discontinue drug if seizure occurs.

• Monitor renal function tests regularly (especially creatinine clearance).

Patient teaching

• Instruct patient to take drug with or without food.

• Instruct patient to swallow tablet whole and not to break, crush, chew, or dissolve it.

Advise patient to discontinue drug and immediately report to prescriber if seizures occur.

• Instruct patient to promptly report urinary tract problems.

• As appropriate, review all other significant and life-threatening adverse reactions.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


(dal-fam-pri-deen) ,


(trade name),


(trade name)


Therapeutic: anti multiple sclerosis agents
Pharmacologic: potassium channel blockers
Pregnancy Category: C


Treatment of mutiple sclerosis, to improve walking speed.


Acts as a potassium channel blocker, which may increase conduction of action potentials.

Therapeutic effects

Increased walking speed in patients with multiple sclerosis.


Absorption: Rapidly and completely absorbed (96%).
Distribution: Unknown.
Metabolism and Excretion: 96% eliminated in urine, 0.5% in feces.
Half-life: 5.2–6.5 hr.

Time/action profile (improvement in walking speed)

POunk3–4 hr24 hr


Contraindicated in: HypersensitivityHistory of seizures;Moderate/severe renal impairment (CCr ≤50 mL/min)(↑ risk of seizures); Lactation: Avoid use.
Use Cautiously in: Mild renal impairment (CCr 51–80 mL/min) (↑ risk of seizures) Geriatric: Consider age-related ↓ in renal function; Obstetric: Use only if potential benefit justifies potential risk to fetus; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • seizures (life-threatening)
  • dizziness
  • headache
  • insomnia
  • weakness

Ear, Eye, Nose, Throat

  • nasopharyngitis
  • pharyngolaryngeal pain


  • constipation
  • dyspepsia
  • nausea


  • urinary tract infection


  • back pain


  • balance disorder
  • multiple sclerosis relapse
  • paresthesia


  • anaphylaxis (life-threatening)


Drug-Drug interaction

None noted.


Oral (Adults) 10 mg twice daily.


Extended-release tablets: 10 mg

Nursing implications

Nursing assessment

  • Assess walking speed in patients with multiple sclerosis prior to and periodically during therapy.
  • Monitor for seizures during therapy, risk increases with increased dose. If seizure occurs, discontinue therapy.
  • Monitor for signs and symptoms of anaphylaxis (dyspnea, wheezing, urticaria, angioedema of the throat or tongue) during therapy.
  • Lab Test Considerations: Monitor creatinine clearance prior to and at least yearly during therapy; renal impairment may require dose reduction or discontinuation.

Potential Nursing Diagnoses

Impaired walking (Indications)


  • Administer tablets twice daily approximately 12 hr apart without regard to food. Administer tablets whole; do not break, crush, chew, or dissolve.

Patient/Family Teaching

  • Instruct patient to take dalfampridine as directed, with approximately 12 hrs between tablets. If a dose is missed, omit and take next scheduled dose on time; do not double doses. May increase risk of seizures. Advise patient to read Medication Guide prior to beginning therapy and with each Rx refill; new information may be available.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • If a seizure or signs or symptoms of anaphylaxis occur, advise patient to notify health care professional immediately, to discontinue dalfampridine, and to report the event to Acorda (manufacturer) at 1-800-367-5109.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

  • Improved walking and increased walking speed in patients with multiple sclerosis.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
In return for the payment to Acorda, HCR obtains the right to receive royalty revenue on Fampyra (prolonged-release fampridine tablets) payable by Biogen, up to an agreed upon threshold of royalties.
Equally significant, Fampyra was granted marketing authorization in the EU.
Fampyra has been proven to help with mobility for those living with the disease and drastically increase their quality of life, but often for an extortionate cost of up to [euro]500 a month.
The study was conducted in Canada and Europe with prolonged-release fampridine (Fampyra), known as dalfampridine (Ampyra) in the United States.
Under the agreement, UCB will receive Biogen Idec's portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA, FAMPYRA, AVONEX, TYSABRI, PLEGRIDY and Daclizumab High-Yield Process (DAC HYP).
M2 PHARMA-May 25, 2017-Biogen's Fampyra Cleared in EU for Improvement of Walking in People with MS
Gerard Murphy, 49, yesterday admitted he is still sceptical about the Government coughing up to provide potentially life-changing drug Fampyra to people with crippling MS.
AMPYRA is known as prolonged-, modified-, or sustained-release fampridine (FAMPYRA) in some countries outside the US.
Gerard Murphy had to give up "miracle" drug Fampyra in January after five years receiving it for free because he couldn't afford it.